Roche Venture Fund
VC Fund
Basel, Switzerland
Roche Venture Fund is a VC fund in Basel focused on Biotechnology and Health Care. The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
- Total investments:
- 120
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries Roche Venture Fund invests in
Stages Roche Venture Fund invests in
Countries Roche Venture Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $7.5M–$86M
- Series B
- $10M–$125M
- Series C
- $5M–$105M
Investment Focus
Industry
- Biotechnology 55 (46%)
- Health Care 34 (28%)
- Therapeutics 22 (18%)
- Medical 20 (17%)
- Pharmaceutical 17 (14%)
Stage
- Series B 39 (33%)
- Series A 29 (24%)
- Series C 16 (13%)
- Series D 9 (8%)
- Funding Round 7 (6%)
Country
- United States 43 (36%)
- United Kingdom 4 (3%)
- Spain 3 (3%)
- France 2 (2%)
- Switzerland 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Carole Nuechterlein
Head of Roche Venture Fund
|
Head of Roche Venture Fund | Total investments: 11 | Find email | |
Monique Schiersing
Investment Director
|
Investment Director | Total investments: 6 | Find email | |
Simon Greenwood
Investment Director
|
Investment Director | Total investments: 2 | Find email | |
Simon Meier
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
Nisha Marathe
Investment Manager
|
Investment Manager | Total investments: 2 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mironid
|
Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network. | $46M / Series B / Aug 05, 2026 | |
Cour Pharmaceuticals Development
|
Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M / Series B / Jun 18, 2026 | |
MISSION Therapeutics
|
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. | $13.3M / Venture - Series Unknown / Oct 15, 2025 | |
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M / Series B / Jun 11, 2025 | |
GlycoEra
|
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M / Series B / May 27, 2025 | |
|
MISSION Therapeutics
|
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. | $32.1M / Series D / Mar 14, 2024 | |
|
Cour Pharmaceuticals Development
|
Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $105M / Series A / Jan 30, 2024 | |
|
GlycoEra
|
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | Series A / Jan 05, 2024 | |
NMD Pharma
|
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $81.4M / Series B / Nov 15, 2023 | |
Aligos Therapeutics
|
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertisein liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules. | $92M / Post-IPO Equity / Oct 23, 2023 | |
| See all 120 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Roche Venture Fund invest in?
Roche Venture Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 120 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Roche Venture Fund's check size?
Roche Venture Fund typically joins rounds of $7.5M–$86M at Series A, $10M–$125M at Series B and $5M–$105M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Roche Venture Fund participates in.
How do I contact Roche Venture Fund?
Public channels for Roche Venture Fund include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Roche Venture Fund?
The team at Roche Venture Fund includes Carole Nuechterlein (Head of Roche Venture Fund), Monique Schiersing (Investment Director) and Simon Greenwood (Investment Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
